Hangzhou Tigermed Consulting Co., Ltd (HNGZY)

Market Cap	6.07B -8.9%
Revenue (ttm)	1.13B +15.8%
Net Income	-60.32M
EPS	-0.04
Shares Out	n/a
PE Ratio	n/a
Forward PE	51.06
Dividend	0.02 (0.41%)
Ex-Dividend Date	Jun 22, 2026

Volume	612
Open	4.280
Previous Close	4.450
Day's Range	4.200 - 4.450
52-Week Range	4.000 - 4.450
Beta	0.44
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 29, 2026

About HNGZY

Hangzhou Tigermed Consulting Co., Ltd, together with its subsidiaries, provides contract research organization services in the People’s Republic of China and internationally. The company offers clinical trial operation services, such as clinical pharmacology, registration and regulatory affairs, scientific affairs, medical translation, pharmacovigilance, real-world research, third-party auditing and training, etc. for innovative drugs, generic drugs, and medical devices, as well as supporting services directly related to clinical trials, includ...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2004
• Employees: 11,130
• Stock Exchange: OTCMKTS
• Ticker Symbol: HNGZY

Financial Performance

In 2025, HNGZY's revenue was 6.83 billion, an increase of 3.48% compared to the previous year's 6.60 billion. Earnings were 887.89 million, an increase of 119.15%.

Financial numbers in CNY

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Nov 9, 2026

Data Sources Report a data error